Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

ShareThe World Health Organisation (WHO) is assembling a Guideline Development Group (GDG) to craft recommendations for the ...

Nov. 27, 2024 — Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring ... HIV Latency Reversing ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...